Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

Gils Roex(University of Antwerp), Sébastien Anguille(Antwerp University Hospital), Feifei Luo(Jiangxi University of Traditional Chinese Medicine), Yiwei Chu(Fudan University), Diana Campillo-Davó(University of Antwerp), Donovan Flumens(University of Antwerp), Kristien Wouters(Antwerp University Hospital), Marijke Timmers(Antwerp University Hospital), Wilfried Schroyens(Antwerp University Hospital), Eva Lion(University of Antwerp), Zwi Berneman(University of Antwerp)
Journal of Hematology & Oncology
December 1, 2020
10.1186/s13045-020-01001-1
Cited by 183

Related Papers

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells
|Blood|2001|458
SIRT5 Desuccinylates and Activates Pyruvate Kinase M2 to Block Macrophage IL-1β Production and to Prevent DSS-Induced Colitis in Mice
|Cell Reports|2017|340
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
|Journal of Neuroinflammation|2018|264
CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus.
|Proceedings of the National Academy of Sciences|1994|221